Highlights for the upcoming 2017–2018 season include the following:1.
The category “no known condition” indicates that the patient did not have any known underlying medical condition indicated in the medical chart at the time of hospitalization.
Therefore, a quadrivalent vaccine with influenza B strains of both lineages would be predicted to offer additional protection, but there is no evidence at this time that a quadrivalent vaccine is more effective.
For the 2017–2018 season, IIV will be available for intramuscular (IM) injection in both trivalent (IIV3) and quadrivalent (IIV4) formulations. The available IIV formulations and age groups for which use is approved are presented in Table 4.
Pediatricians should attempt to promptly identify children suspected of having influenza infection for timely initiation of antiviral treatment, when indicated, to reduce morbidity and mortality.
Best results are seen when treated within 48 hours of symptom onset.